EN

Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Campus life

Discover the campuses

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Join our programs

Shaker Program Program Gene.iO ATIGE Program

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Directories Our network

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Come to our events

Partnering Week

Innovate with us

Discover >

Quick access

Company

Pymabs

5 rue Henri Desbruères – Building 7
91030 EVRY Cedex – FRANCE
Phone: +33 1 78 05 47 31
Email: andeol.falcon@pymabs.com

Andéol FALCON DE LONGEVIALLE: President & CSO
Pymabs - Genopole's Company Pymabs - Genopole's Company

#Industrial Biotech #Biomanufacturing / Pharmaceutical Services #R&D Services and Products #Therapeutics

  • Recombinant antibodies
  • Therapeutic proteins
  • Transient expression
  • plant system

Field of Activity

R&D services in the field of transient expression of recombinant proteins in plants.

BACKGROUND
Created in April 2017, Pymabs is a spin-off of the Genopole Plant Process Innovation laboratory.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Benefiting from Medicago’s high-throughput discovery platform (VLPExpress), Pymabs provides proofs of concepts for antibody expression in the setting of therapeutics. Its services range from antibody development to in vitro testing .
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
Collaboration with Medicago (Canadian Biopharmaceutical company).
COLLABORATIONS SOUGHT
Companies developing antibodies for therapeutic purposes and wishing to test an alternative biomanufacturing approach on an industrial scale.

  • Further Information

    ANNUAL TURNOVER: 380 k€
    1 Patent being written
    3 Staff members
    < strong >STRENGTHS:
    Speedy development and rapid transfer from R&D to bioproduction.
    < strong >INNOVATION ASSETS:
    Glycomodulation.

Share
Genopole’s Companies

#Therapeutics

In same field

DeepTope - Genopole's company

Deeptope

– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodies

Discover
Phagos - Genopole's Company

PHAGOS

At Phagos, we use bacteria’s natural predator, the bacteriophage, to overcome infectious diseases in aquaculture.

Discover
Theranovir - Genopole's Company

Theranovir

Biotechnology, R&D, Drug development, oncology, obesity, infectious diseases

Discover
Wiratech Europe - Genopole's Company

Wiratech Europe

Wiratech Europe is a healthcare company that uses scientific knowledge of human variability and instrumental technologies to provide innovative tests, devices and services.

Discover
Vaccinopole - entreprise génopolitaine

Vaccinopole

Production of BCG vaccines and BCG-based cancer and inflammation treatments, preparation and distribution of fresh log-phase BCG cultures.

Discover
Synsight - Genopole's Company

Synsight

Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

Discover
Santen - Genopole's Company

Santen

Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.

Discover
Pharnext - Genopole's company

Pharnext SA

Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).

Discover
Pharming - Genopole's company - Logo 2021

PHARMING

Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Discover
PEP-Therapy - Genopole's Company - logo 2021

PEP-Therapy

PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

Discover
Genosafe - Genopole's Company

Genosafe

GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.

Discover
Généthon - Genopole's Laboratory

Généthon

Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.

Discover
Eukarÿs - Genopole's company

Eukarÿs

Synthetic gene therapy for the treatment of severe human liver diseases and tools for the bioproduction of recombinant proteins and viruses using the proprietary expression system C3P3.

Discover

Enterome

Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.

Discover
Logo Ab Science - Genopole's company

AB Science

Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.

Discover
View all >
With the support from

Keep up to date with Genopole’s latest events and news